Hong Jae Chon

Associate Professor

CHA Bundang Medical Center

South Korea

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

40%

Pharmacology

10%

Tumor Immunology

40%

Immunotherapy

30%

Targeted Therapy

30%

Cancer Biology

20%

Tyrosine Kinase

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

Article Link

Year:

2023

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Article Link

Year:

2023

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Article Link

Year:

2023

ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

Article Link

Year:

2023

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply

Article Link

Year:

2023

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Article Link

Year:

2023

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Article Link

Year:

2023

Multifunctional porous microspheres encapsulating oncolytic bacterial spores and their potential for cancer immunotherapy

Article Link

Year:

2023

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.

Article Link

Year:

2022

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma

Article Link

Year:

2022

Collaborators11

Seul-Gi Kim

Clinical Associate Professor

CHA Bundang Medical Center

SOUTH KOREA

Han Sang Kim

Associate Professor

Yonsei Cancer Center

SOUTH KOREA

Beom Kyung Kim

Yonsei University College of Medicine

SOUTH KOREA

Chang Woo Kim

Professor

Ajou University School of Medicine

SOUTH KOREA

Sung Hwan Lee

CHA University

SOUTH KOREA

ilhwan kim

Associate Professor

Inje University Ilsan Paik Hospital

SOUTH KOREA

Sanghoon Jung

Assistant Professor

CHA Bundang Medical Center

SOUTH KOREA

Wooram Park

Assistant Professor

Sungkyunkwan University

SOUTH KOREA

Incheon Kang

Assistant Professor

CHA Bundang Medical Center

SOUTH KOREA

Chan Kim

Assistant Professor

CHA University School of Medicine

SOUTH KOREA

Hannah Yang

University of Michigan

UNITED STATES

How do I reach out?

Meet Kite AI